Continuous culture of urine-derived bladder cancer cells for precision medicine

Shuai Jiang; Jiaqi Wang; Chen Yang; Renke Tan; Jun Hou; Yuan Shi; Huihui Zhang; Shiyu Ma; Jianan Wang; Mengmeng Zhang; George Philips; Zengxia Li; Jian Ma; Wanjun Yu; Guohua Wang; Yuanming Wu; Richard Schlegel; Huina Wang; Shanbo Cao; Jianming Guo; Xuefeng Liu; Yongjun Dang

doi:10.1007/s13238-019-0649-5

PDF(2001 KB)

Protein Cell ›› 2019, Vol. 10 ›› Issue (12) : 902-907. DOI: 10.1007/s13238-019-0649-5

LETTER

Continuous culture of urine-derived bladder cancer cells for precision medicine

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Shuai Jiang, Jiaqi Wang, Chen Yang, Renke Tan, Jun Hou, Yuan Shi, Huihui Zhang, Shiyu Ma, Jianan Wang, Mengmeng Zhang, George Philips, Zengxia Li, Jian Ma, Wanjun Yu, Guohua Wang, Yuanming Wu, Richard Schlegel, Huina Wang, Shanbo Cao, Jianming Guo, Xuefeng Liu, Yongjun Dang. Continuous culture of urine-derived bladder cancer cells for precision medicine. Protein Cell, 2019, 10(12): 902‒907 https://doi.org/10.1007/s13238-019-0649-5

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Anjanappa M, Hao Y, Simpson ER, Bhat-Nakshatri P, Nelson JB, Tersey SA, Mirmira RG, Cohen-Gadol AA, Saadatzadeh MR, Li L (2018) A system for detecting high impact-low frequency mutations in primary tumors and metastases. Oncogene 37:185–196 CrossRef Google scholar

[2]	Berdik C (2017) Unlocking bladder cancer. Nature 551:S34–S35 CrossRef Google scholar

[3]	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132 CrossRef Google scholar

[4]	Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM (2017) Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer 16:80 CrossRef Google scholar

[5]	Jin L, Qu Y, Gomez LJ, Chung S, Han B, Gao B, Yue Y, Gong Y, Liu X, Amersi F (2018) Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture. Oncotarget 9:11503–11514 CrossRef Google scholar

[6]	Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810 CrossRef Google scholar

[7]	Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279–290

[8]	Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R (2015) Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med 3:36

[9]	Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V (2012) ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180:599–607 CrossRef Google scholar

[10]	Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093–1098 CrossRef Google scholar

[11]	Rubio-Perez C, Tamborero D, Schroeder MP, Antolin AA, Deu-Pons J, Perez-Llamas C, Mestres J, Gonzalez-Perez A, Lopez-Bigas N (2015) In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27:382–396 CrossRef Google scholar

[12]	Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K (2017) Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. Eur Urol 71:319–327 CrossRef Google scholar

[13]	Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185 CrossRef Google scholar